Free Trial
NASDAQ:LXEO

Lexeo Therapeutics Q3 2026 & Study result Earnings Date & Estimates

Lexeo Therapeutics logo
$2.87 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.61 +0.74 (+25.78%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexeo Therapeutics is estimated to report Q3 2026 & Study result earnings on Monday, December 14, 2026.

Upcoming Earnings Announcement

Quarter
Q3 2026 & Study result
Announcement Date
Live Event
Earnings Conference Call
Lexeo Therapeutics Q3 2026 & Study result
00:00 / 00:00
Live Transcript
Follow Audio

What Analysts Expect from Lexeo Therapeutics in Q3 2026 & Study result

Lexeo Therapeutics is expected to post earnings of -$0.3222 per share. In the same quarter a year earlier Lexeo Therapeutics reported -$0.33 per share. Lexeo Therapeutics last reported on August 12, 2026, posting -$0.30 per share and missing the -$0.2852 consensus estimate. Lexeo Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3222
Prior-Year EPS
-$0.33

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.30 (Missed by -$0.0148)
EPS Beat Rate
5 of last 8 quarters

Lexeo Therapeutics Q3 2026 & Study result Earnings FAQ

Lexeo Therapeutics (NASDAQ:LXEO) is estimated to report Q3 2026 & Study result earnings on Monday, December 14, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Lexeo Therapeutics' Q3 2026 & Study result earnings conference call is scheduled for Monday, November 16, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Lexeo Therapeutics to post earnings of -$0.3222 per share for Q3 2026 & Study result.

Lexeo Therapeutics Earnings Headlines

Trump, Schiff and Dalio all point to the same warning sign
In 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.tc pixel
See More Lexeo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email.

About Lexeo Therapeutics

Lexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations.

The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Founded in 2017, Lexeo is based in New York and conducts research and clinical development in the United States. As a clinical-stage company, it focuses on advancing its pipeline rather than marketing approved therapies.

View Lexeo Therapeutics Profile